← All trials
NCT04250636
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Feb 28, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rockefeller UniversityLead sponsor
- Cornell UniversityCollaborator
- Rockefeller UniversityOverall official - principal investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of PennsylvaniaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.